A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies

NCT00871559 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

83

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Malignancies

Interventions

DRUG: REGN421(SAR153192)

Sponsor

Regeneron Pharmaceuticals

Collaborators

[object Object]